KOD Kodiak Sciences Inc.
Kodiak Sciences Inc. (KOD) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.94 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +10.6% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Kodiak Sciences Inc.
Kodiak Sciences Inc. is a clinical stage biopharmaceutical company engaged in developing novel therapeutics to treat chronic, high-prevalence retinal diseases, which are the major causes of blindness. The company's proprietary antibody biopolymer conjugate (ABC) platform is designed to maintain potent and effective drug levels in ocular tissues for longer periods than the currently-marketed biologic medicines for treating retinal diseases.
Sector
Healthcare
Industry
Biotechnology